Table 1.
CD9 | CD53 | CD81 | CD82 | CD151 | CD63 | CD37 | |
---|---|---|---|---|---|---|---|
α3β1 | + | + | + | + | + | + | + |
α4β1 | + | + | + | + | ND | + | ND |
α6β1 | + | + | + | + | + | + | ND |
α5β1 | + | ND | + | + | ND | + | ND |
Precursor β1 | + | ND | – | – | ND | – | ND |
αIIbβ3 | + | ND | ND | ND | ND | ND | ND |
α6β4 | – | ND | – | ND | + | – | ND |
CD11/CD18 | ND | ND | ND | ND | ND | + | ND |
HLA‐DR | ND | + | + | + | ND | + | + |
HLA‐DM | ND | ND | ND | + | ND | + | ND |
HLA‐DQ | ND | + | + | + | ND | ND | ND |
HLA‐DO | ND | ND | ND | + | ND | + | ND |
EGF‐R | ND | ND | ND | + | ND | ND | ND |
TGF‐α | + | ND | ND | ND | ND | ND | ND |
FGFR | + | ND | + | ND | ND | ND | ND |
c‐Met | + | ND | ND | + | ND | ND | ND |
HB‐EGF | + | ND | –? | –? | ND | ND | ND |
FRPP | + | ND | + | ND | ND | ND | ND |
EWI‐2 | + | ND | + | + | ND | ND | ND |
EWI‐F | ND | ND | + | ND | ND | ND | ND |
CD36 | + | ND | ND | ND | ND | ND | ND |
CD9P‐1 | + | ND | + | + | + | + | ND |
CD2 | ND | + | ND | ND | ND | ND | ND |
CD4 | ND | ND | + | + | ND | ND | ND |
CD8 | ND | ND | + | + | ND | ND | ND |
CD21‐CD19‐Leu13 | ND | ND | + | ND | ND | ND | ND |
CD19 | + | ND | + | + | ND | ND | ND |
CD20 | ND | + | + | + | ND | ND | ND |
CD46 | + | ND | + | + | + | ND | ND |
Protein kinase C | + | + | + | + | + | – | – |
Phosphatidylinositol 4‐kinase | + | – | + | – | + | + | ND |
Dectin‐1 | ND | ND | ND | ND | ND | ND | + |
Syntenin 1 | ND | ND | ND | ND | ND | + | ND |
γ‐Glutamyl transpeptidase | ND | + | + | + | ND | ND | ND |
Green (+), positive interaction; red (–), no interaction; EGF‐R, epidermal growth factor receptor; EWI, Ewing; FGFR, fibroblast growth factor receptor; FRPP, prostaglandin F2α receptor regulatory protein; HB‐EGF, heparin‐binding epidermal growth factor; HLA, human leukocyte antigen; ND, not determined; TGF, transforming growth factor.